Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -0.59% 16.90 11,206,677 16:09:57
Bid Price Offer Price High Price Low Price Open Price
16.80 17.00 18.60 16.75 17.125
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.12 -18.35 -4.80 58
Last Trade Time Trade Type Trade Size Trade Price Currency
16:26:26 O 4,531 16.83 GBX

Kromek (KMK) Latest News

More Kromek News
Kromek Investors    Kromek Takeover Rumours

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
16/1/202115:08Kromek Group PLC3,869
21/8/201709:01Kromek Group (KMK) - Overvalued AIM mugging181

Add a New Thread

Kromek (KMK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

DateSubject
16/1/2021
08:20
Kromek Daily Update: Kromek Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 17p.
Kromek Group Plc has a 4 week average price of 10.10p and a 12 week average price of 10.10p.
The 1 year high share price is 27.25p while the 1 year low share price is currently 7.80p.
There are currently 344,559,089 shares in issue and the average daily traded volume is 7,423,225 shares. The market capitalisation of Kromek Group Plc is £58,230,486.04.
15/1/2021
12:10
33mick: Varies From LSE yest morning...a good post by Promethium, I hope he doesn't mind me posting part of it again here. He gives his view re- the China issue. "Promethium Price: 13.70 Strong Buy My thoughts to help clarify / deal with confusionThu 08:38 I see some confusion and misconceptions here - a pity, KMK is an amazing prospect. Doubts expressed by some people might be making some of you unduly nervous. My background is I’m finance qualified and a significant shareholder. Just my opinions of course, does not constitute advice. DYOR and feel free to comment.",,....................................................................,.....,,,............................. Recommend you concentrate on core businesses (nuclear detection and medical imaging, security screening), market positions, proven products and growth potential. Exciting enough on their own. Bio-hazard detection is incredible, would an amazing bonus on top. Ventilators I see as a distraction, was never intended to be a core product. "Provision for Chinese contract (£13m): A firm planned date when the contract would be delivered was needed for auditors. No firm date in sight, so had to make provision. Final results were delayed until Oct, waiting for clarity. KMK can only reverse this provision when they can get their engineers on a flight into China, test and commission the solution in situ, and finally handover the order. Arnab has said cannot do this remotely from the UK or the US, they need to be physically there. So all depends on UK / China travel restrictions. Product is sitting in KMK warehouse at nil value ready to ship. Arnab assures us that client relationship still strong and just a matter of time. When delivered, provision will be reversed, giving windfall £13m benefit to profit".
13/1/2021
11:23
varies: No mention in today's report of the £13 million of AROC written off in 2019/20. These Amounts Recoverable on Contracts were due from Chinses customers and go back a couple of years, I believe. The report for the year to 30 April 2020 (issued in October) told us that KMK had made serious efforts to recover these until January 2020 when the Covid outbreak rendered the financial position of these customers "uncertain" and so a full provision was made against the balance due to KMK. The Board expressed confidence then that this position would reverse. The lack of any news on this front is disappointing. Even a 50% recovery of this balance would make a great difference to KMK.
04/1/2021
09:39
slicethepie: Well said, having lost the support of his largest shareholder Miton, I hope Arnab looks at the share price and sees what we all see ...a massive underperformer. The recent departure of two very experienced individuals in the chairman and fd does not help as they could probably stand up to him the boardroom, newcomers may not have the confidence.
23/12/2020
13:22
33mick: From this time last year which was on track to be a record? year revenue wise untill the Covids hit the world. Kromek have announced I think 3 or 4 positive new products / potential products that should have a material impact on the bottom line. The main event for me being the bio pathogen DARPA program whitch is weeks away from first London field trails. None of this is factored into today's share price...just bumping off a 5 year low. But I have sympathy for the recent comments about how long it's taken to come good...maybe 2021 is Kromek's year, let's hope so!
17/12/2020
19:45
earwacks: Thanks Sev22. Absolutely correct if Mito were off loading on the open market we 'd be at about 5p! The Schroder trade possibly coincides with Mitons last sell, sounds an equal amount. I had the same query with SWG recently . All these huge trades had gone through without crippling the share price The director told me they were not notifiable and matched trades. Yesterday Spreadex notification came through that they had taken a million! What on earth would a share betting company be doing buying a stock like that? Anyway the director said he was surprised but not complaining. The other trading world where who knows what goes on!
26/11/2020
09:34
b00mb0y: Supernumerary, I can assure you that I am not fake. I can’t tell you enough how much I want this share to rise! As I have said, I’ve been in this since the IPO. I hold 300000 shares at a cost of £67,000. My lowest purchase price was about two month ago at .111p my largest and my highest purchase price was .49p in 2014. My breakeven is at .205. I could have made a profit at some stage but decided to let it ride for bigger profit. Im not sure as to why my posting history tells you I’m fake but I can assure you that I’m not. JimTech, I agree with what you say about the walletinvestor website but it’s not good reading when you don’t want to see it. After all that I have researched (and I’m not the best company researcher in the world - if only) on KMK, I do believe, myself, that it will come good. Having said that, I’ve been in a very similar position with another stock, MTFB, only to have lost the lot and I really can’t afford for this to happen again. Oh, I’ve got more than my fingers crossed here, Jt. Come on KMK. GET YOUR FINGER OUT!
25/11/2020
20:57
b00mb0y: All this sounds good for KMK. However, according to walletinvester.com KMK’s share price will drop to .06157 in 12 month and possibly crash. Check out the above website for the information / view they give on KMK. I’ve been invested in KMK since it’s IPO only to watch it dwindle to this sad share price figure. WTF is going to get this share price back up to give us a MC over £100m again. Getting well pi55ed off now!
03/11/2020
14:26
sev22: I am highlighting this article, published by Simon Thompson on the 7th October 2020, just to reassure those who are still invested here. If anything the news flow has improved since this update so I am surprised to see so many investors bailing out. Kromek (KMK:8p), a Sedgefield-based radiation detection technology company focused on the medical, security screening and nuclear markets, has announced annual results today. The Covid-19 impact on the business led to Kromek reporting an underlying cash loss of £400,000 on 9 per cent lower revenue of £13.1m. This had already been flagged at the time of the pre-close trading update from the £27.5m market capitalisation company (‘Stock picking value open to future gains’, 4 May 2020). Of far more interest is Kromek’s subsequent $5.2m (£4m) contract extension by the Defence Advanced Research Projects Agency (DARPA), an agency of the US Department of Defence, for work on developing a mobile bio-security system capable of detecting airborne pathogens. That’s because the project is now expected to be expanded for use in the non-military sector in response to the outbreak of Covid-19. Kromek has already developed a prototype to sample air and identify the presence of any biological pathogen – including Covid-19 or any mutant version that may emerge over time. The technology can be used to immediately flag the presence of someone with a contagious disease and allow effective mitigation of the risk of transmission. By placing samplers in high footfall areas, such as airports and hospitals, or where people are in close proximity for long periods, threats can be identified without having to individually test people. Knowing a carrier is infected with a disease before they infect further individuals is key to halting the onset of an outbreak and before it causes major global disruption. Non-military applications include use in shopping centres, sports arenas, theme parks, schools, hospitals, offices, airplanes, and cruise ships. Importantly, it’s incredibly accurate, giving a false alarm in just one in 800,000 tests. Chief executive Arnab Basu revealed during this morning’s results call that Kromek will undertake field trials with the pre-production prototype collecting airborne samples from urban and rural locations starting in January, and has field tests scheduled in London with two UK government agencies: The Defence Science and Technology Laboratory (DSTL), an executive agency of the Ministry of Defence; and Defence Aviation Repair Agency (DARA). Kromek also plans for delivery of units for pilot deployment in the US in the first half of 2021. It could be a saviour for the UK government given the problems it’s facing with its much maligned Covid-19 test and trace programme. It could also reverse the fortunes for shareholders who have seen the share price decline since hitting a 12-month high of 27p in May, losing two-thirds of its value and taking the price well below the 17.5p level of my repeat buy call in early May. Share price decline The major reason for today’s share price fall is that Kromek unexpectedly revealed a £13.1m write-down on a medical imaging contract due to Covid-19 which has disrupted both the shipment to hospitals and access onsite. Work in progress had been stockpiled for delivery and recognised as revenue over the course of the past 30 months. With shipment originally scheduled for 2020 onwards now delayed, the carrying value of accounts receivable under contract (AROC) is dependent on Kromek being able to prove a shipping date. It is unable to provide this at present, hence the £13.1m write-down to AROC in the accounts. However, all the stock remains on Kromek's balance sheet (and in its UK facilities) ready for shipment and delivery in the future, hence why the directors still expect the position to reverse, at which point Kromek can book a hefty exceptional credit. I am not sure investors have fully grasped this accounting point. Kromek’s rebound potential I am not sure they have grasped that a rebound in the 2020/21 financial year is on the cards either. Firstly, Kromek has now started delivering on a delayed seven-year Original Equipment Manufacturer (OEM) contract worth US$58m (£45m) to provide its cutting edge CZT detectors and advanced electronics in state-of-the-art medical imaging detectors. The contract should deliver revenues worth “millions of dollars” in the current financial year, says Mr Basu. The same is true of another delayed contract from the 2019/20 financial year. Secondly, the company continues to win new contracts in other parts of the business. Kromek was awarded $1.1m worth of contracts to add technical innovation capability to its D3S ‘dirty bomb detectors’ by US government agencies. They are proving popular in Europe, too, with the European Commission and Irish Civil Defence also using them. Given the heightened terrorism risk across the world, the 22 countries currently deploying the technology is likely to grow. Thirdly, Mr Basu reassuringly notes that Kromek’s revenue is now back to pre-Covid-19 levels following the disruption of the first quarter to 31 July 2020. That’s important as it means that concerns over the company’s cash position should now ease, another reason for the share price fall since May. Finance director Derek Bulmer says that the company had gross cash of £9.4m at 30 April 2020 and gross debt of £5.6m. Since then it has strengthened its gross cash reserves by over £2m and varied bank covenants on its HSBC facility. Given that revenue has returned to pre-Covid-19 levels, and stocks are now being delivered on delayed contracts, the company should have the funding in place to operate without the need to tap shareholders. This may not have been made clear to investors. The bottom line is that the 40 per cent share price discount to net asset value of 13p should reverse when investors cotton onto the huge commercial opportunities for Kromek's ground breaking DARPA airborne pathogens technology that is being piloted. Strong Buy.
07/10/2020
11:05
sev22: A Simon Thompson update 'hot off the press' issued at mid-day today. A Tech winner in fight against Covid-19. Kromek (KMK:8p), a Sedgefield-based radiation detection technology company focused on the medical, security screening and nuclear markets, has announced annual results today. The Covid-19 impact on the business led to Kromek reporting an underlying cash loss of £400,000 on 9 per cent lower revenue of £13.1m. This had already been flagged at the time of the pre-close trading update from the £27.5m market capitalisation company (‘Stock picking value open to future gains’, 4 May 2020). Of far more interest is Kromek’s subsequent $5.2m (£4m) contract extension by the Defence Advanced Research Projects Agency (DARPA), an agency of the US Department of Defence, for work on developing a mobile bio-security system capable of detecting airborne pathogens. That’s because the project is now expected to be expanded for use in the non-military sector in response to the outbreak of Covid-19. Kromek has already developed a prototype to sample air and identify the presence of any biological pathogen – including Covid-19 or any mutant version that may emerge over time. The technology can be used to immediately flag the presence of someone with a contagious disease and allow effective mitigation of the risk of transmission. By placing samplers in high footfall areas, such as airports and hospitals, or where people are in close proximity for long periods, threats can be identified without having to individually test people. Knowing a carrier is infected with a disease before they infect further individuals is key to halting the onset of an outbreak and before it causes major global disruption. Non-military applications include use in shopping centres, sports arenas, theme parks, schools, hospitals, offices, airplanes, and cruise ships. Importantly, it’s incredibly accurate, giving a false alarm in just one in 800,000 tests. Chief executive Arnab Basu revealed during this morning’s results call that Kromek will undertake field trials with the pre-production prototype collecting airborne samples from urban and rural locations starting in January, and has field tests scheduled in London with two UK government agencies: The Defence Science and Technology Laboratory (DSTL), an executive agency of the Ministry of Defence; and Defence Aviation Repair Agency (DARA). Kromek also plans for delivery of units for pilot deployment in the US in the first half of 2021. It could be a saviour for the UK government given the problems it’s facing with its much maligned Covid-19 test and trace programme. It could also reverse the fortunes for shareholders who have seen the share price decline since hitting a 12-month high of 27p in May, losing two-thirds of its value and taking the price well below the 17.5p level of my repeat buy call in early May. Share price decline The major reason for today’s share price fall is that Kromek unexpectedly revealed a £13.1m write-down on a medical imaging contract due to Covid-19 which has disrupted both the shipment to hospitals and access onsite. Work in progress had been stockpiled for delivery and recognised as revenue over the course of the past 30 months. With shipment originally scheduled for 2020 onwards now delayed, the carrying value of accounts receivable under contract (AROC) is dependent on Kromek being able to prove a shipping date. It is unable to provide this at present, hence the £13.1m write-down to AROC in the accounts. However, all the stock remains on Kromek's balance sheet (and in its UK facilities) ready for shipment and delivery in the future, hence why the directors still expect the position to reverse, at which point Kromek can book a hefty exceptional credit. I am not sure investors have fully grasped this accounting point. Kromek’s rebound potential I am not sure they have grasped that a rebound in the 2020/21 financial year is on the cards either. Firstly, Kromek has now started delivering on a delayed seven-year Original Equipment Manufacturer (OEM) contract worth US$58m (£45m) to provide its cutting edge CZT detectors and advanced electronics in state-of-the-art medical imaging detectors. The contract should deliver revenues worth “millions of dollars” in the current financial year, says Mr Basu. The same is true of another delayed contract from the 2019/20 financial year. Secondly, the company continues to win new contracts in other parts of the business. Kromek was awarded $1.1m worth of contracts to add technical innovation capability to its D3S ‘dirty bomb detectors’ by US government agencies. They are proving popular in Europe, too, with the European Commission and Irish Civil Defence also using them. Given the heightened terrorism risk across the world, the 22 countries currently deploying the technology is likely to grow. Thirdly, Mr Basu reassuringly notes that Kromek’s revenue is now back to pre-Covid-19 levels following the disruption of the first quarter to 31 July 2020. That’s important as it means that concerns over the company’s cash position should now ease, another reason for the share price fall since May. Finance director Derek Bulmer says that the company had gross cash of £9.4m at 30 April 2020 and gross debt of £5.6m. Since then it has strengthened its gross cash reserves by over £2m and varied bank covenants on its HSBC facility. Given that revenue has returned to pre-Covid-19 levels, and stocks are now being delivered on delayed contracts, the company should have the funding in place to operate without the need to tap shareholders. This may not have been made clear to investors. The bottom line is that the 40 per cent share price discount to net asset value of 13p should reverse when investors cotton onto the huge commercial opportunities for Kromek's ground breaking DARPA airborne pathogens technology that is being piloted. Buy.
04/9/2020
12:58
sev22: Simon Thompson wrote the article below 4 months ago. This morning the shares have dropped to 13.0p which seems a massive over reaction to no news. Kromek’s valuable IP materially undervalued. A trading update from Kromek (KMK:17.5p), a radiation detection technology company focused on the medical, security screening and nuclear markets, prompted a 12 per cent share price markdown that simply isn’t warranted. True, Covid-19 restrictions means that two key contracts will be postponed until the new financial year, the impact of which is that Kromek will break even on a cash profit basis in the 12 months to 30 April 2020. However, the contracts have only been delayed, not lost. There is clearly demand for its products as highlighted by the massive ventilator order I commented on in mid-April (‘Stockpicking for bear market gains’, 16 Apr 2020). Moreover, analyst Paul Hill at Equity Development points out that Kromek is well advanced on its US Department of Defence contract to develop a groundbreaking vehicle biological threat detector that rapidly detects any airborne pathogen used in germ warfare. Mr Hill understands that the “same first-of-its-kind science can also accurately and consistently recognise Covid-19” and could have “substantial benefits for many non-military applications, such as shopping centres, sports arenas, theme parks, schools, hospitals, offices, airplanes, and cruise ships”. This is certainly not being priced in, nor is the real possibility of additional ventilator orders. The shares offer 100 per cent upside to my 35p target price. Buy.
Kromek share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
KMK
Kromek
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210116 22:13:07